Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

Christine Miaskowski, Bruce A. Cooper, Michelle Melisko, Lee May Chen, Judy Mastick, Claudia West, Steven M. Paul, Laura B. Dunn, Brian Schmidt, Marilyn Hammer, Frances Cartwright, Fay Wright, Dale J. Langford, Kathryn Lee, Bradley Aouizerat

Research output: Contribution to journalArticle

Abstract

BACKGROUND A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated. METHODS Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. RESULTS Three distinct subgroups of patients were identified (ie, 36.1% in Low class; 50.0% in Moderate class, and 13.9% in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. CONCLUSIONS Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.

Original languageEnglish (US)
Pages (from-to)2371-2378
Number of pages8
JournalCancer
Volume120
Issue number15
DOIs
StatePublished - Aug 1 2014

Fingerprint

Outpatients
Drug Therapy
Therapeutics
Quality of Life
Gastrointestinal Neoplasms
Symptom Assessment
Social Class
Social Support
Comorbidity
Lung Neoplasms
Breast
Demography

Keywords

  • chemotherapy
  • latent class analysis
  • precision medicine
  • quality of life
  • symptom clusters
  • symptom profiles

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. / Miaskowski, Christine; Cooper, Bruce A.; Melisko, Michelle; Chen, Lee May; Mastick, Judy; West, Claudia; Paul, Steven M.; Dunn, Laura B.; Schmidt, Brian; Hammer, Marilyn; Cartwright, Frances; Wright, Fay; Langford, Dale J.; Lee, Kathryn; Aouizerat, Bradley.

In: Cancer, Vol. 120, No. 15, 01.08.2014, p. 2371-2378.

Research output: Contribution to journalArticle

Miaskowski, C, Cooper, BA, Melisko, M, Chen, LM, Mastick, J, West, C, Paul, SM, Dunn, LB, Schmidt, B, Hammer, M, Cartwright, F, Wright, F, Langford, DJ, Lee, K & Aouizerat, B 2014, 'Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy', Cancer, vol. 120, no. 15, pp. 2371-2378. https://doi.org/10.1002/cncr.28699
Miaskowski, Christine ; Cooper, Bruce A. ; Melisko, Michelle ; Chen, Lee May ; Mastick, Judy ; West, Claudia ; Paul, Steven M. ; Dunn, Laura B. ; Schmidt, Brian ; Hammer, Marilyn ; Cartwright, Frances ; Wright, Fay ; Langford, Dale J. ; Lee, Kathryn ; Aouizerat, Bradley. / Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. In: Cancer. 2014 ; Vol. 120, No. 15. pp. 2371-2378.
@article{25e46c3af94343ec9559776b875c1d13,
title = "Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy",
abstract = "BACKGROUND A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated. METHODS Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. RESULTS Three distinct subgroups of patients were identified (ie, 36.1{\%} in Low class; 50.0{\%} in Moderate class, and 13.9{\%} in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. CONCLUSIONS Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.",
keywords = "chemotherapy, latent class analysis, precision medicine, quality of life, symptom clusters, symptom profiles",
author = "Christine Miaskowski and Cooper, {Bruce A.} and Michelle Melisko and Chen, {Lee May} and Judy Mastick and Claudia West and Paul, {Steven M.} and Dunn, {Laura B.} and Brian Schmidt and Marilyn Hammer and Frances Cartwright and Fay Wright and Langford, {Dale J.} and Kathryn Lee and Bradley Aouizerat",
year = "2014",
month = "8",
day = "1",
doi = "10.1002/cncr.28699",
language = "English (US)",
volume = "120",
pages = "2371--2378",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

TY - JOUR

T1 - Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy

AU - Miaskowski, Christine

AU - Cooper, Bruce A.

AU - Melisko, Michelle

AU - Chen, Lee May

AU - Mastick, Judy

AU - West, Claudia

AU - Paul, Steven M.

AU - Dunn, Laura B.

AU - Schmidt, Brian

AU - Hammer, Marilyn

AU - Cartwright, Frances

AU - Wright, Fay

AU - Langford, Dale J.

AU - Lee, Kathryn

AU - Aouizerat, Bradley

PY - 2014/8/1

Y1 - 2014/8/1

N2 - BACKGROUND A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated. METHODS Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. RESULTS Three distinct subgroups of patients were identified (ie, 36.1% in Low class; 50.0% in Moderate class, and 13.9% in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. CONCLUSIONS Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.

AB - BACKGROUND A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated. METHODS Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. RESULTS Three distinct subgroups of patients were identified (ie, 36.1% in Low class; 50.0% in Moderate class, and 13.9% in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. CONCLUSIONS Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.

KW - chemotherapy

KW - latent class analysis

KW - precision medicine

KW - quality of life

KW - symptom clusters

KW - symptom profiles

UR - http://www.scopus.com/inward/record.url?scp=84904604275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904604275&partnerID=8YFLogxK

U2 - 10.1002/cncr.28699

DO - 10.1002/cncr.28699

M3 - Article

C2 - 24797450

AN - SCOPUS:84904604275

VL - 120

SP - 2371

EP - 2378

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 15

ER -